Tin tức & Cập nhật

The next-generation ROS1 and TRK tyrosine kinase inhibitor (TKI) repotrectinib has demonstrated high response rates and durable activity in patients with ROS1 fusion–positive non-small-cell lung cancer (NSCLC), regardless of whether they have previously received ROS1 TKI therapy, according to phase II results of the ongoing registrational TRIDENT-1 trial.

Primary tumour resection (PTR) in combination with chemotherapy (C) appears beneficial to a specific subgroup of patients with unresectable colorectal mucinous adenocarcinoma with liver metastasis (UCR-MAC-LM) compared with PTR or C alone, suggests a study.

A voice-based conversational artificial intelligence application helps type 2 diabetes (T2D) patients navigate basal insulin titration at home and, in turn, achieve rapid glycaemic control, as reported in a study.

Restarting treatment with maintenance olaparib in ovarian cancer patients who had received one prior poly(ADP-ribose) polymerase (PARP) inhibitor and at least two lines of platinum-based chemotherapy results in a modest but significant improvement in progression-free survival (PFS) compared with placebo, results of a phase III study have shown.

Testicular cancer survivors (TCSs) demonstrate similar health-related quality of life (HRQoL) to that of the general population at a median of 28 years since treatment initiation, reports a study.